These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 20440741)

  • 1. Contingent triple-screening for Down syndrome in the second trimester is not a cost-effective prenatal screening strategy in Mainland Chinese population.
    Li DZ
    Prenat Diagn; 2010 May; 30(5):493. PubMed ID: 20440741
    [No Abstract]   [Full Text] [Related]  

  • 2. Contingent triple-screening for Down syndrome in the second trimester: a feasibility study in Mainland Chinese population.
    Xie Z; Lu S; Li H
    Prenat Diagn; 2010 Jan; 30(1):74-6. PubMed ID: 19967750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost-effectiveness analysis of prenatal screening strategies for Down syndrome.
    Odibo AO; Stamilio DM; Nelson DB; Sehdev HM; Macones GA
    Obstet Gynecol; 2005 Sep; 106(3):562-8. PubMed ID: 16135588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-trimester maternal serum screening for Down syndrome in Mainland China.
    Liao C; Huang Y; Li D; Song S; Yi C; Zhou J
    Prenat Diagn; 2006 Dec; 26(13):1271-2. PubMed ID: 17139699
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparing outcomes and costs between contingent and combined first-trimester screening strategies for Down's syndrome.
    Martín I; Gibert MJ; Aulesa C; Alsina M; Casals E; Bauça JM
    Eur J Obstet Gynecol Reprod Biol; 2015 Jun; 189():13-8. PubMed ID: 25827079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First- and second-trimester evaluation of risk for Down syndrome.
    Ball RH; Caughey AB; Malone FD; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Emig D; D'Alton ME;
    Obstet Gynecol; 2007 Jul; 110(1):10-7. PubMed ID: 17601890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First- and second-trimester screening: detection of aneuploidies other than Down syndrome.
    Breathnach FM; Malone FD; Lambert-Messerlian G; Cuckle HS; Porter TF; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Klugman S; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Tripp T; Bianchi DW; D'Alton ME;
    Obstet Gynecol; 2007 Sep; 110(3):651-7. PubMed ID: 17766613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum screening in a Japanese population.
    Sehmi IK; Jones RG; Gordon Y; Cuckle HS
    Prenat Diagn; 2000 May; 20(5):437-9. PubMed ID: 10820418
    [No Abstract]   [Full Text] [Related]  

  • 9. [Analysis of Down syndrome screening by maternal serum detection in mid-pregnancy].
    Liu YH; Li LF; Wu YM
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):532-4, 537. PubMed ID: 20335129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Trisomy 21 screening: value of ultrasound and serum markers in a combined approach].
    Senat MV; Rozenberg P; Bernard JP; Ville Y
    J Gynecol Obstet Biol Reprod (Paris); 2001 Feb; 30(1):11-27. PubMed ID: 11240502
    [No Abstract]   [Full Text] [Related]  

  • 11. The variation of risk estimates through pregnancy in second trimester maternal serum screening for Down syndrome.
    Christiansen M; Høgdall EV; Larsen SO; Høgdall C
    Prenat Diagn; 2002 May; 22(5):385-7. PubMed ID: 12001192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Serum screening of fetal chromosome abnormality during second pregnancy trimester: results of 26,803 pregnant women in Jiangsu Province].
    Hu YL;
    Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(35):2476-80. PubMed ID: 18067809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated serum screening for Down syndrome in primary obstetric practice.
    Knight GJ; Palomaki GE; Neveux LM; Smith DE; Kloza EM; Pulkkinen AJ; Williams J; Haddow JE
    Prenat Diagn; 2005 Dec; 25(12):1162-7. PubMed ID: 16231402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An outcomes analysis of five prenatal screening strategies for trisomy 21 in women younger than 35 years.
    Biggio JR; Morris TC; Owen J; Stringer JS
    Am J Obstet Gynecol; 2004 Mar; 190(3):721-9. PubMed ID: 15042005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimates for the sensitivity and false-positive rates for second trimester serum screening for Down syndrome and trisomy 18 with adjustment for cross-identification and double-positive results.
    Benn PA; Ying J; Beazoglou T; Egan JF
    Prenat Diagn; 2001 Jan; 21(1):46-51. PubMed ID: 11180240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-trimester prenatal screening markers for Down syndrome in women with insulin-dependent diabetes mellitus.
    Huttly W; Rudnicka A; Wald NJ
    Prenat Diagn; 2004 Oct; 24(10):804-7. PubMed ID: 15503275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated, sequential, and contingent screening for Down syndrome - local needs should drive methodology.
    Wyatt P
    Prenat Diagn; 2007 Feb; 27(2):186-7. PubMed ID: 17266162
    [No Abstract]   [Full Text] [Related]  

  • 18. Predicting the result of additional second-trimester markers from a woman's first-trimester marker profile: a new concept in Down syndrome screening.
    Maymon R; Cuckle H; Jones R; Reish O; Sharony R; Herman A
    Prenat Diagn; 2005 Dec; 25(12):1102-6. PubMed ID: 16231324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down's syndrome risk estimates demonstrate considerable heterogeneity despite homogeneity of input.
    Reynolds T; Ellis A; Jones R
    Ann Clin Biochem; 2004 Nov; 41(Pt 6):464-8. PubMed ID: 15588435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of first- and second-trimester serum markers after storage and shipment.
    Lambert-Messerlian GM; Eklund EE; Malone FD; Palomaki GE; Canick JA; D'Alton ME
    Prenat Diagn; 2006 Jan; 26(1):17-21. PubMed ID: 16378319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.